Rapidus and PwC highlighted Fábio Rosa as one of 34 young promising Scanian personalities and driven entrepreneurs of this year.
Asgard Therapeutics highlighted at the Medicon Valley Alliance/ Øresundsinstituttet report
In a new survey published by Øresund Institute and Medicon Valley Alliance, Asgard Therapeutics was highlighted as one of 426 life science companies in Skåne.
Filipe Pereira awarded with Mats Paulsson Grant 2020
Mats Paulsson Foundations awarded Filipe Pereira, co-founder of Asgard Therapeutics, with a Mats Paulsson Grant 2020. Since 2019, the foundation has focused on grants for academic research projects that in the near future can lead to socially beneficial innovations.
Filipe Pereira awarded with the KiiLN Postdoctoral Entrepreneurship Award
The KiiLN- Keystone for Incubating Innovation in Life Sciences Network team and Icahn School of Medicine at Mount Sinai awarded Filipe Pereira, co-founder of Asgard Therapeutics, the KiiLN Postdoctoral Entrepreneurship Award. This award recognizes Filipe’s efforts in entrepreneurship addressing unmet needs in life sciences.
Asgard Therapeutics becomes a SmiLe member
Asgard Therapeutics AB has been admitted to SmiLe Incubator as the next step to move forward on the pre-clinical studies of their lead program TrojanDC.
https://news.smileincubator.com/posts/pressreleases/immunotherapy-company-asgard-therapeutics-is
Asgard featured on the Pharma Industry report about ATMPs in Sweden
Advanced Therapies Medical Products (ATMPs) are considered the “drugs of the future”. These are based on gene, cell and tissue products. Sweden has the ambitious goal of becoming a leader in ATMPs and for this it is important to manage research efforts in an efficient way, facilitating the clinical translation of such innovative therapies. Within this thematic, Pharma Industry Publishing AB published a report on the development of ATMPs in Sweden, where Asgard Therapeutics was featured.
Filipe Pereira, Cristiana Pires and Fábio Rosa, co-founders of Asgard Therapeutics, awarded with the Lund University and Sparbanken Skåne’s prize for future innovations
Together with Sparbanken Skåne, in collaboration with the Sparbanksstiftelsen Finn, Lund University awarded Filipe Pereira, Cristiana Pires and Fábio Rosa the Lund University and Sparbanken Skåne’s prize for future innovations. The award is intended to promote and encourage the utilization of knowledge at Lund University.
https://www.lu.se/index.php/artikel/framtidens-innovationer-prisade-i-lund
Filipe Pereira, co-founder of Asgard Therapeutics, awarded with a BII PreSeed grant
The BioInnovation Institute (BII) awarded Filipe Pereira, co-founder of Asgard Therapeutics, with DKK 3.5M to advance pre-clinical development of dendritic cell reprogramming and define its regulatory roadmap towards the clinic.
Asgard Therapeutics awarded Vinnova’s Innovative Startup Step 2
Swedish start-up company Asgard Therapeutics has been awarded the second step of Vinnova’s Innovative Startup program in order to further develop a new cancer immunotherapy based on dendritic cell reprogramming.
Asgard Therapeutics awarded with Lund University Innovation VFT+ Funds
Asgard was selected to receive Vinnova’s VFT+ funds managed by LU Innovation for verification activities of TrojanDC towards partners, customers and investors.